OBJECTIVES: Isolated lung perfusion with gemcitabine is an effective technique for the treatment of lung metastases in an experimental model. In clinical studies, increased toxicity has been observed when combining intravenous gemcitabine with radiotherapy (RT). The goal of our study was to determine whether RT in combination with isolated lung perfusion increases lung toxicity.
INTRODUCTION
Worldwide, cancer is the second most prevalent cause of death [1] . Half of the patients diagnosed with cancer die, mostly due to metastatic disease. Besides the lymph nodes, the lungs are the most frequent site of metastases. The incidence of lung metastases is estimated at 50% of all non-pulmonary cancers [2] . Currently, the treatment of isolated pulmonary metastases of an adenocarcinoma consists of metastasectomy followed by adjuvant systemic chemotherapy, which yields a 5-year survival of 30-40% [3, 4] .
Treatment with intravenous (IV) chemotherapy is dose-limited due to systemic toxicity in healthy tissues. The latter can be avoided by the use of isolated lung perfusion (Ilup). With this technique, chemotherapy reaches the lungs by selective perfusion of the pulmonary artery without systemic exposure, which yields a higher concentration of chemotherapeutic drugs at the site of the tumour [5] . Ilup with melphalan has proven to be effective in experimental models, in which a significant reduction in the number of pulmonary nodules and a prolonged survival was obtained compared to IV administration.
Besides melphalan, gemcitabine is an effective drug in the treatment of metastases of adenocarcinoma [6] . Previous studies show that higher concentrations of gemcitabine in the lung are reached by Ilup compared with IV administration [7] . This results in a reduction in the number of pulmonary metastases and a better survival. However, survival percentages were lower compared to Ilup with melphalan.
Preclinical and clinical investigations show that the use of gemcitabine in combination with radiotherapy (RT) results in a synergistic effect, which indicates that gemcitabine is a radiosensitizer [6, 8] .
The synergistic effect of gemcitabine depends on the concentration of gemcitabine in the irradiated tissue and on the time interval between administration of IV gemcitabine and RT. The latter is optimal after 24-60 h [6, 9, 10] . On the contrary, an optimal combination of therapies also causes more toxicity on healthy tissue and surrounding organs. Due to this toxicity, the use of IV gemcitabine in combination with RT is limited [11] [12] [13] [14] [15] . In order to exploit the synergistic effect to a maximum, gemcitabine should reach the tumour in high concentration and should not be distributed to other organs or surrounding tissue. The latter can be achieved by using Ilup [16] .
The toxic effect of Ilup with gemcitabine in combination with RT on lung tissue is currently unknown. In this experimental study, we evaluate the toxic effect of this combined therapy on healthy lung tissue in a rat model. Short-and long-term pathological changes are evaluated. Results of this study may have practical implications for further research.
MATERIALS AND METHODS

Animals
Male inbred Wag-Rij strain rodents with a weight between 250 and 300 g were used for all experiments. All animals were treated according to the Animal Welfare Act and the 'Guide for the Care and Use of Laboratory Animals'. All experimental protocols were approved by the Ethical Committee of the University of Antwerp.
Protocol
Four different treatments are compared: no treatment, IV GCB, Ilup voluven and Ilup GCB. Each treatment was administered with or without RT. Hence, all rodents were randomized into eight treatment groups (Table 1) . Each group was divided into two subgroups according to the time of sacrifice, except for the sham group. Time intervals were chosen according to the expected pathological changes. The first subgroup (subgroup A) was sacrificed 2 weeks after treatment, the second (subgroup B) 3 months after treatment.
A sham group, consisting of four animals, was sacrificed without treatment. One group was treated with Ilup with hydroxyethyl starch (HES) to document the damage caused by Ilup.
For the same reason, a group with Ilup HES and RT was included in this study.
Radiotherapy
Rodents in these groups were treated with a radiation dose of 8 Gy, administered in one fraction [17] . They were sedated during irradiation by intraperitoneal injection of a mixture of ketamine (50 mg/ml) and xylazine (20 mg/ml) in a ratio of 3:1. This mixture was administered at a dose of 0.2 ml/kg. During sedation, they were placed in a plastic box on their back with the four limbs stretched out to obtain optimal exposure of the thorax.
Chemotherapy
Gemcitabine (Gemzar®) was dissolved in saline at a concentration of 20 mg/ml. The dose administered was 40 mg/kg, which is the same for IV as for use with Ilup. At this dosage, an acceptable toxicity was found in earlier studies [7] . When using Ilup, the dose was diluted in HES to a volume of 12.5 ml to be administered at a speed of 0.5 ml/min.
Combination therapy
When a combination of gemcitabine and RT was given, a fixed time interval was chosen in order to optimalize the radiosensitizing characteristic of gemcitabine [6, 18, 19] . Gemcitabine acts as a radiosensitizer through different mechanisms.
First of all, gemcitabine can induce cellular apoptosis. This prevents proliferation of cells and so repopulation. When combining gemcitabine with RT, it diminishes the potential of the cell to repair genomic damage, caused by ionizing irradiation. While gemcitabine is mainly active in dividing cells, RT also causes damage in non-dividing cells, which adds an extra opportunity. Since there will be additional cell damage, there will be better oxygenation in surviving tumour cells, which makes them more sensitive for RT. In order to obtain the radiosensitizing effect, an interval of 24-60 h needs to be respected when administering combination therapy [6, 9, 10] . An interval of 24 h was used for all experiments in our study.
Left isolated lung perfusion
Isolated left lung single-pass perfusion was performed according to a modified technique described by Hendriks et al. [20] . Rodents were anaesthetized with isoflurane in a mixture of nitrous oxide (NO 2 ) and oxygen (O 2 ). Isoflurane was administered at a concentration of 4% and the NO 2 :O 2 ratio was 3:1. After 5 min, rodents were intubated and ventilated with a volume-controlled ventilator. Animals were kept under anaesthesia using a mixture of nitrous oxide and oxygen in combination with isoflurane, of which the dose was based on pupil and muscle relaxation [6] . Subsequently, the left chest was shaved. A left thoracotomy was performed between the third and fourth intercostal space to obtain access. The left lung was luxated anteriorly and the pulmonary artery and vein were dissected and clamped with microclips. A PE-10 catheter was inserted into the pulmonary artery through a small arteriotomy and fixed with a 4-0 silk tie. The catheter was used to perfuse the lung. The effluent was collected at the venous side by suction in proximity of the venotomy. In all experiments, rats were perfused for 25 min followed by a 5-min washout with buffered starch at a rate of 0.5 ml/min.
Pathology
Rodents of subgroups A and B were sacrificed after 2 weeks or 3 months as described earlier by the use of a lethal mixture of isoflurane and nitrous oxide. Immediately after death, the lungs and heart were dissected en bloc by sternotomy. A mixture of 4% paraformaldehyde, dissolved in a phosphate buffer with a pH of 7.5, was used for fixation of the lungs. After fixation, the lungs were divided in three different sites: apex, hilum and base. The latter to evaluate the presence of a difference in pathologic changes according to the site of prelevation, which would indicate different toxicity levels at different sites of the lung. Of every zone, two slices were made for light microscopic examination. Expected pathologic changes range from mild damage to the lung or an interstitial pneumonitis after IV administration of gemcitabine to radiopneumonitis and fibrosis after irradiation. Based on the expected changes, haematoxylin-eosin (HE) stain and Perls stain were chosen [17, 21, 22] . Slices with Perls staining were categorized using a semi-quantitative scoring system based on the number of siderophages in the slice (Table 2 ) [23, 24] . This score varies from score 0 in normal lung tissue, to severe damage with a great amount of siderophages (score 3). Slices obtained from the sham group were used as a reference for normal lung tissue. All slices comparable to reference slices were scored as normal lung tissue.
They were all scored twice to account for intra-observer variability. In HE slices, fibrosis, necrosis and inflammation were studied [23] . When observing fibrosis and necrosis, the percentage of pathologic tissue was scored to the overall slice. Subsequently, a cumulated score of these parameters, called pathological damage in this study, was calculated, and divided into different categories: 0% normal, 1-20% mild, 21-40% moderate, 41-60% moderately severe, 61-80% severe and 81-100% very severe. Inflammation was scored based on the number of infiltrates per slice.
Statistics
Results were analysed using stepwise mixed-effects logistic regression, accounting for the dependency of observations within the same individual (three slices per animal) by including a random intercept term. For the mixed logistic regression on Perls staining, the score was dichotomized into a normal/mild category and a moderate/severe category. The mixed logistic regression on HES staining was performed by dichotomizing the observations into an undamaged group (absence of fibrosis/ necrosis) and a group with either fibrosis or necrosis.
For all regression models, independent variables included: treatment (blank, IV gcb, illup voluven and illup gcb), RT ( present or absent), the location of the slice (apex, hilum, base) and the interaction between treatment and RT. Variable selection was performed using stepwise backward regression, comparing the nested models with a likelihood ratio test. To avoid problems with complete separation, the blank category was omitted from the logistic regression models, and only the active treatments were compared. Mixed models were fitted using the nlme and lme4 packages in the statistical program R, version 2.13.1. Post hoc testing was performed using the multcomp package in R, with the Tukey correction for multiple testing. Results were significant with a P-value < 0.05.
RESULTS
Perls stain
According to the semi-quantitative scoring system as described earlier, all 264 slices were examined twice in a variable order. In 24 slices, a different score was given at a second look, which leads to an acceptable intra-observer variability of 9% for the total group. When slices, which were given different scores, were observed for a third time, the same score as at the second evaluation was found.
Seventy-three slices showed normal lung tissue (28% of total group); 24% of slices showed mild pathologic changes, 29% moderate changes and 50 slices (19% of total) were scored as severe damage (Table 3) . Slices of rodents treated with RT alone showed normal lung tissue in 83%. If pathologic changes were found, which were more frequent after early sacrifice, there was only mild damage.
After IV administration of gemcitabine, normal and mild tissue changes were found, apart from a few exceptions which showed moderate damage.
Adding RT to the treatment showed only minor changes. In the short-term group, two slices were evaluated as moderate changes. After Ilup with HES, there was more damage with an increase in alveolar siderophages compared with the former treatment modalities. Only one slice was scored as normal. The greatest amount of slices showed moderate changes (47%). Adding RT to Ilup showed an increase in moderate changes. The percentage of severe histopathologic changes was comparable to Ilup with HES alone.
After Ilup with gemcitabine, an increase in lung tissue changes was found compared to the other treatment modalities, with severe pathologic changes in 58% of the slices. In the early group, there were twice as many severely changed slices than in the long-term group.
Animals treated with combined Ilup gemcitabine and RT showed comparable results as the group who was only treated with Ilup gemcitabine.
Histologic changes do not depend on specific lung region (P = 0.057). Therefore, the latter was not included into the logistic regression model. Animals were divided into two subgroups with different time periods of sacrifice. Normal lung tissue was mainly found in slices of animals that were sacrificed on the short term. Of the total slices with score 0, 68% was sacrificed after 2 weeks. Slices of animals sacrificed after 3 months were mainly scored as mild or moderate (73% of slices with mild change and 59% slices with moderate change). Slices with severe damage were more common in animals that were sacrificed on the short term (70%). The time of sacrifice was omitted from the logistic regression model, because it was not significant (P = 0.50) ( Table 4) .
Results HE stain
As described earlier, slices with HE stain were scored based on three characteristics: percentage of fibrosis, percentage of necrosis and number of infiltrates per slice. The score based on the number of infiltrates was not included in our study for different reasons. First, animals are not specific pathogen free and are kept together which makes it impossible to detect the origin of an inflammatory infiltrate. Even in the sham group, inflammatory infiltrates were present, often even more frequent than in treated groups. Secondly, the size of the infiltrate could not be quantified. In the following results, only fibrosis and necrosis were taken into account. The latter was only present in five slices. Therefore, scores for fibrosis and necrosis were considered together as 'pathologic changes' and subdivided in categories as described earlier (Table 5 ).
All slices which showed necrosis were from the group treated with Ilup. In four of the five cases, slices were from the group which was treated with a combination therapy of Ilup gemcitabine and RT. The fifth slice was treated with Ilup HES. Slices from the sham group all showed normal lung tissue. RT alone showed no changes to the lung tissue on the short term. On the long term, 11% of the slices showed mild fibrosis. After treatment with RT, we mainly found pathologic changes on the long term.
IV administration of gemcitabine showed comparable results, with in one slice very mild fibrosis on the long term. When IV gemcitabine and RT were administered, no pathologic changes were found in contrast to what is expected due to the radiosensitizing effect of gemcitabine.
Ilup, without gemcitabine, showed on short-term mild histologic changes in 39% of the slices. On the long term, 17% of the slices showed abnormal findings, of which 6% was graded as moderate. When adding RT to Ilup, comparable results were found. On the short term, 28% of the slices showed moderate pathologic changes, which is less compared to Ilup alone.
Ilup with gemcitabine showed in all cases lung tissue changes scored as mild, moderate or moderately severe. On the long term, there seems to be some repair of changes, with 44% of 
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slices categorized as normal. Mild pathologic changes are the most common finding. When adding RT, the same percentage of damage in the slices is found. On the long term, there is some repair in damage with normal slices in 33.3%. The effect of time of sacrifice is significant with a P-value of 0.037, and was implemented in the model of logistic regression which is further used. The origin of the slice had no significant influence on outcome (P = 0.369) ( Table 6 ).
Results of descriptive statistics
When comparing the results on HE stain and Perls stain, we found the expected pathologic changes on short term and long term after treatment with RT. On the short term, siderophages were present on Perls stain and fibrosis is found on the long term on HE stain. Combination of IV gemcitabine with RT mainly showed siderophages on Perls stain on the long term. Treatment with Ilup showed a lot of siderophages and fibrosis on the short term, which is repaired on the long term. When adding RT, pathologic changes increase on the long term on both stains. On the short term, only siderophages increase. Perfusion with gemcitabine increases pathologic changes, such as increased fibrosis and haemosiderosis.
Adding RT gives a minimal increase in fibrosis and haemosiderosis.
If we compare the results of both stains, pathologic changes are comparable with significantly more changes when Ilup is administered.
Comparison between groups
For both stains, significant differences between groups were detected using stepwise mixed-effects logistic regression.
Besides the influence of treatment on pathologic changes, the effect of time of sacrifice was also evaluated. The latter had no significant influence on pathologic changes on Perls stain (P = 0.500) but had an influence on pathologic damage on HE stain (P = 0.037). For both for HES and Perl staining, the presence of RT and the location of the tissue did not have a significant effect on the tissue damage. Treatment modality has a significant influence on histopathology (likelihood ratio < 0.001) ( Table 7) . IV gemcitabine was chosen as a reference group, since this is the current standard treatment of choice. Post hoc testing showed that compared to IV GCB, isolated lung perfusion with HES showed significant more damage (P = 0.025). Isolated lung perfusion with GCB showed more damage, compared to IV GCB and Ilup HES (P < 0.001). Rodents who were only irradiated showed a comparable damage on both stains. Ilup with HES induces significantly more damage than treatment with IV gemcitabine. RT had no significant effect on pathologic changes, and was not included in the model of regression.
DISCUSSION
Treatment of isolated pulmonary metastases of adenocarcinoma currently consists of metastasectomy with adjuvant chemotherapy with a 5-year survival of 30-40% [4] . Chemotherapy is dose limited due to systemic toxicity, which can be avoided using Ilup [5] . Gemcitabine is effective as a treatment for metastatic adenocarcinoma and improved survival with less systemic toxicity was demonstrated in a rat model of Ilup [7] . Due to the radiosensitizing characteristics of gemcitabine, combination with RT could improve survival [6, 8] . This combined treatment has not yet been studied in vivo. The goal of this study was to compare pathologic changes after combination therapy to IV gemcitabine and RT alone. If no severe pathologic changes are found, the efficacy of the technique can be further studied in experimental and clinical models. Moderate changes were present after treatment with IV gemcitabine or RT alone. When administering gemcitabine, haemosiderosis was found. After treatment with RT, mild fibrosis was detected on long-term evaluation. These findings are in accordance with the literature [22] . When combining both treatment modalities, comparable to even slightly diminished changes on HE stain were present compared to both modalities alone.
Treatment with Ilup gemcitabine causes additional damage in both stains, compared to treatment with gemcitabine or RT. This result can be explained by the inflammation caused by the technique of Ilup, which was proven to be present in the group which was treated with Ilup with HES.
Lung tissue of rodents who underwent Ilup with gemcitabine showed on Perls stain moderate (36%) to severe (58%) intra-alveolar haemosiderosis. On HE stain, we also found moderate and severe pulmonary fibrosis.
When combining Ilup with RT, comparable results were found on Perls staining. HE-stained slices showed mild additional damage, which was not significant. Three slices showed severe pathologic changes in which 80-100% of the total slice showed fibrotic and necrotic lesions. Since these slices were found in the same rodent, no conclusion can be drawn from this isolated result.
In this study, we administered gemcitabine at a dose of 40 mg/ kg, which is based on earlier experiments by Van Putte et al. [7] . This represents the maximum tolerated dose in our experimental model. Experiments in vitro show that gemcitabine induces radiosensitization at concentrations thousand times smaller than concentrations reached with therapeutical dosages [25] .
The interval between administering chemotherapy and RT is also of great value to exploit the effect of radiosensitization. In vivo studies compared the influence of different gemcitabine dosages and different time intervals until radiation. These studies showed that the time interval between chemotherapy and RT is more important than the dose of gemcitabine. The synergistic effect is maximal after 24 h, which has been respected in this study [6, 10] .
An important finding in our results is the absence of additional pathologic changes when combining IV gemcitabin with RT. This is in contrast to in vitro and in vivo preclinical and clinical studies where increased toxicity has been described in different tissues, including lung tissue [6, 8, 11, 15] . This toxicity consists mainly of haematologic damage which manifests itself as neutropenia and trombopenia. Oesophagitis and pneumonitis are also frequently found and can even be lethal. The systemic side effects are avoided when RT is combined with Ilup [7, [11] [12] [13] [14] [15] .
Controlled clinical trials are necessary to study this effect in human lung tissue. The optimal dosage of RT and gemcitabine, and the time interval has to be explored.
Ilup with gemcitabine caused in our model significantly more changes than standard treatment modalities such as IV gemcitabine and RT. On both stains, moderate to severe pathological changes were found. On the one hand, we expect an increase in changes since Ilup is invasive and may also cause ischaemiareperfusion damage [7] . On the other hand, the pathologic changes that are found are more extensive than in earlier studies. In the latter, based on six observations of animals sacrificed after 3 months, normal lung tissue was found in 66.7%, in contrary to our results in which 44% of slices showed normal lung tissue. If fibrosis was present, there was only mild to moderate fibrosis [7] . Due to these findings, the procedure of Ilup was extensively compared to the one used in earlier experiments. In the present study, commercially available gemcitabine (Gemzar®) containing additives was used in contrast to previous experiments where the pure form of gemcitabine was utilized. Whether these additives cause additional lung damage has to be explored further.
The initial goal of this study was to detect pathologic changes when Ilup with gemcitabine is combined with RT. Ilup on itself already induces significant changes to lung tissue, but adding RT does not increase lung toxicity. This experimental model shows that Ilup with gemcitabine and RT is feasible. To determine the precise radiosensitizing effect of Ilup with gemcitabine, subsequent experimental studies are necessary using lung metastatic models. Also, specific effects on lung function parameters should be evaluated in further studies.
In conclusion, since there is currently a rather low survival rate after surgical treatment of lung metastases [4] , combined treatment modalities should be evaluated in order to improve survival. Our findings suggest that treatment with Ilup and concomitant RT is feasible, and can be used as a model for subsequent studies.
APPENDIX. CONFERENCE DISCUSSION
Dr R. Schmid (Berne, Switzerland): I have a few questions. I think the study is clear and the results are clear, but when you do chemotherapy, you give it in cycles because you want to treat different cells in different stages of the mitosis, and if you do intraoperative chemotherapy, you only do it at one time point, and you add radiation at the same time point, so you always hit the same cells in the same stage. This is the principal question of feasibility of this study.
The second question is on the dosage. You commented on it at the end of your presentation and I'm a bit confused. On one side you give gemcitabine as a chemotherapy and on the other side you give it as a radiosensitizer. If you give it as a radiosensitizer, you can give a much lower dose, and you do radiotherapy with a radiosensitizer. So you better turn around the principle and give IV gemcitabine and intraoperative radiotherapy for these patients. This is the second question-two questions in one. One is the dosage of gemcitabine and the second is the value of the radiotherapy.
Dr Van Thielen: The dosage of gemcitabine is 40 mg/kg for intravenous as well as during isolated lung perfusion. It's the maximum tolerated dose that we used from earlier studies. Of course, we also want to use the effect of the radiosensitization and we wanted to study the toxicity of both modailities combined. But you are right, for radiosensitization, only minimal doses are necessary.
Dr Schmid: And then you could give it repetitively, not only at one time point. What is your comment on that, on the treatment modality?
Dr Van Thielen: I would like to ask Professor Van Schil to comment on that question.
Dr P. Van Schil (Antwerp, Belgium): You are right on the dose, but this was in fact a toxicity study. We know from clinical practice that when you combine intravenous gemcitabine with radiotherapy, you can induce acute toxicity. So we wanted to use the maximum tolerated dose we could give in isolated lung perfusion, and combine that with radiotherapy. We were a bit surprised. We thought we would find some more toxicity in the lung parenchyma, and fortunately this was not the case. So we start with the highest dose and then we can decrease it gradually.
The second part of your question, we combine isolated lung perfusion in those patients with resectable lung metastasis as adjuvant therapy, but of course you are right, you can only do it once. We are currently developing a kind of pulmonary artery catheter with balloon occlusion to give repetitive pulmonary artery infusion. When you are able do it by a balloon catheter, you can repeat it several times, and then it's really as with standard chemotherapy, you can give 4 to 6 cycles and evaluate response.
